To understand the imaging sequence for Yttrium-90 microsphere therapy
Liver directed XRT are limited in scope -Radiation tolerance of normal hepatocytes < neoplastic tissue -Max. tolerated doses 30-40 Gy (Emami et al, IJROBP 21, 1991; McGinn et al, J Clin Onc 16, 1998) With 90 Y-microspheres, total liver radiation doses up to 80 Gy were well tolerated with no hepatic radiation damage (Gray et al, Annals Oncology 12, 2001; Burton et al, Radiology 175, 1990) 90 Y-microsphere therapy is approved by the FDA for the treatment of unresectable HCC and metastatic colorectal cancer 6 AAPM 2012 Annual Meeting S. Cheenu Kappadath, PhD Properties of Decay: Y-90 (β -, 64.1 hr) Zr-90; a pure β -emitter -Y-90 also emits β + at low yields (~32 ppm) via internal pair-production β energy: 0.937 MeV (mean) and 2.28 MeV (max) Tissue penetration depth: 2.5 mm (mean) and 11 mm (max) 90 Y deposits >90% of its energy in the first 5 mm of tissue 90 Y deposits >90% of its energy in the first 11 days Permanently implanted 90 Y can deliver radiation absorbed doses of ∼50 Gy for 1 GBq of activity per kilogram of tissue (Sarfaraz et al., Med Phys 31, 2004 ) (Berger, JNM 12, 1971 MAA is a sub-optimal surrogate for microspheres -Biologic degradation time 1-3 hours free 99mTc-pertechnatate -Free 99mTc biodistribution differs from MAA; thyroid & stomach uptakes free 99mTc  introduce error in LSF -Non-spherical shape; Size range 10-to-100 µm Additional objective measures of response -Tumor volume reduction is the mainstay (Gray et al, Aus & NZ J Surgery 62, 1992; Van Hazel et al, J Sur Onc 88, 2004; Lau et al, IJROBP 40, 1998; Sangro et al, IJROBP 66, 2006) -Metabolic response: observed in higher proportion than an CT-based anatomical response for mCRC (p<0.0002) (Wong et al, EJNMMI 29, 2002 ) -Functional response: >50% change in TLG at 6 weeks for mCRC lesions with tumor doses >46 Gy (Flamen et al, PMB 53, 2008) 
